JP2022116001A5 - - Google Patents

Download PDF

Info

Publication number
JP2022116001A5
JP2022116001A5 JP2022077195A JP2022077195A JP2022116001A5 JP 2022116001 A5 JP2022116001 A5 JP 2022116001A5 JP 2022077195 A JP2022077195 A JP 2022077195A JP 2022077195 A JP2022077195 A JP 2022077195A JP 2022116001 A5 JP2022116001 A5 JP 2022116001A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
formula
pharmaceutical composition
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022077195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022116001A (ja
Filing date
Publication date
Priority claimed from PCT/US2015/023060 external-priority patent/WO2015148962A1/en
Application filed filed Critical
Publication of JP2022116001A publication Critical patent/JP2022116001A/ja
Publication of JP2022116001A5 publication Critical patent/JP2022116001A5/ja
Pending legal-status Critical Current

Links

JP2022077195A 2014-03-28 2022-05-09 神経変性疾患を治療するための組成物および方法 Pending JP2022116001A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461971862P 2014-03-28 2014-03-28
US61/971,862 2014-03-28
PCT/US2015/023060 WO2015148962A1 (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases
JP2017502942A JP7255967B2 (ja) 2014-03-28 2015-03-27 神経変性疾患を治療するための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017502942A Division JP7255967B2 (ja) 2014-03-28 2015-03-27 神経変性疾患を治療するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2022116001A JP2022116001A (ja) 2022-08-09
JP2022116001A5 true JP2022116001A5 (https=) 2023-04-12

Family

ID=54196457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017502942A Active JP7255967B2 (ja) 2014-03-28 2015-03-27 神経変性疾患を治療するための組成物および方法
JP2022077195A Pending JP2022116001A (ja) 2014-03-28 2022-05-09 神経変性疾患を治療するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017502942A Active JP7255967B2 (ja) 2014-03-28 2015-03-27 神経変性疾患を治療するための組成物および方法

Country Status (22)

Country Link
US (4) US9802925B2 (https=)
EP (1) EP3122743B1 (https=)
JP (2) JP7255967B2 (https=)
KR (2) KR20160130853A (https=)
CN (3) CN116139282A (https=)
AU (2) AU2015237253B2 (https=)
BR (1) BR112016022575A2 (https=)
CA (1) CA2944211C (https=)
DK (1) DK3122743T3 (https=)
ES (1) ES2939959T3 (https=)
FI (1) FI3122743T3 (https=)
IL (1) IL248074B (https=)
MX (2) MX382453B (https=)
MY (1) MY184878A (https=)
NZ (1) NZ724718A (https=)
PL (1) PL3122743T3 (https=)
RU (1) RU2742773C2 (https=)
SG (2) SG10202001065SA (https=)
SI (1) SI3122743T1 (https=)
TW (2) TWI839623B (https=)
WO (1) WO2015148962A1 (https=)
ZA (1) ZA201606673B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
TWI622380B (zh) * 2017-01-17 2018-05-01 正崴精密工業股份有限公司 生理訊號測量裝置及其血氧濃度演算方法
WO2019055913A1 (en) * 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
EP4267117B1 (en) * 2020-12-23 2026-04-08 Celgene Corporation Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS6033439B2 (ja) 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
JPS56125361A (en) 1980-03-07 1981-10-01 Sagami Chem Res Center Azetidinone compound
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
GB9204001D0 (en) 1992-02-25 1992-04-08 Jacobs Suchard Ag Process for producing reduced fat nuts
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
AU4713293A (en) 1992-07-13 1994-01-31 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
EP0655055B1 (en) 1992-08-13 2000-11-29 Warner-Lambert Company Tachykinin antagonists
FR2696178B1 (fr) 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
ATE158580T1 (de) 1993-05-06 1997-10-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
EP0939632B1 (en) 1996-02-23 2005-10-05 Eli Lilly And Company NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
DE69826487T2 (de) 1997-07-30 2005-12-01 Wyeth Trizyclische vasopressin-agonisten
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
ES2258980T3 (es) 1999-08-16 2006-09-16 Revaax Pharmaceuticals Llc Composiciones farmaceuticas que comprenden acido clavulanico o derivados del mismo para el tratamiento de trastornos del comportamiento.
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
ES2666188T3 (es) 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
AU2002359761A1 (en) 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005035492A1 (en) 2003-10-03 2005-04-21 Serenix Pharmaceuticals, Llc. 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1669776A1 (de) 2004-12-11 2006-06-14 Leica Geosystems AG Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
AU2006227199A1 (en) * 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CA2608718A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
KR101523776B1 (ko) * 2005-07-19 2015-05-28 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
WO2007109615A2 (en) * 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
WO2008034032A2 (en) 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
CA2665851A1 (en) 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
US8362037B2 (en) 2007-03-23 2013-01-29 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
US20090182011A1 (en) * 2008-01-16 2009-07-16 University Of Illinois Chicago Chimeric Nitrate Esters and Use of the Same in a Treatment for Depression
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
WO2019055913A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY

Similar Documents

Publication Publication Date Title
JP2022116001A5 (https=)
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
Penning et al. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: a potent inhibitor of poly (ADP-ribose) polymerase (PARP) for the treatment of cancer
NO20073667L (no) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
AU2004247487B2 (en) N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
RU2006112845A (ru) Производные хиназолина
JP2020534274A5 (https=)
US20140309192A1 (en) Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
CA2386515A1 (en) Piperazine derivatives
JP2004521117A5 (https=)
RU2009122197A (ru) Производные 1,2,4-триазолы в качестве ингибиторов сигма-рецептора
RU2000128036A (ru) Амидиновые соединения
CY1109493T1 (el) Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις
JP2008510828A5 (https=)
EA200300718A1 (ru) Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
BRPI0507506A (pt) compostos
CA2466965A1 (en) Sulphonamide derivatives, their preparation and use as medicaments
JP2007505931A5 (https=)
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
EP4696376A3 (en) Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CA2667387A1 (en) New benzamide derivatives as bradykinin antagonists
JP2009528318A5 (https=)
RU2472781C2 (ru) Новые соединения 707 и их применение
IL171894A (en) Aztidine compounds, preparations and pharmaceutical preparations containing them